Celldex Therapeutics, Inc. (CLDX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$28.27-5.55%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CLDX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -53.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
CLDX — CFO transition
Dated 2026-07-15
Chief Financial Officer — Sam Martin: Sam Martin plans to retire as Chief Financial Officer, with a transition period until March 31, 2027.
Why it matters: The readout will test barzolvolimab in another disease. Clear benefit could support wider use; a miss would limit this path.
Watch forThe Phase 2 study meets its primary endpoint and shows a clear benefit over placebo.
Also watch forThe Phase 2 study misses its main goal or shows no clear benefit over placebo.
Why it matters: These results will show whether CDX-622 changes asthma-related measures in people. A clear change would support its next steps.
Watch forThe asthma study finds changes in FeNO, eosinophil count, or other blood markers. These changes support drug activity.
Also watch forThe asthma study finds no meaningful change in FeNO, eosinophil count, or other blood markers.
Why it matters: Celldex has no material revenue and reported rising costs. Cash updates can show whether planned work remains funded through 2028.
Worry ifAt the next earnings update, Celldex still says its cash can fund planned operations through 2028.
Less concerning ifCelldex shortens its cash runway below 2028 or reports a need for new funding sooner.
Why it matters: A filing would move barzolvolimab from trial results toward a possible U.S. launch. A delay would push that step back.
Supportive ifCelldex submits the BLA to the FDA in 2027, as planned.
Worry ifCelldex reports that the BLA filing is delayed beyond 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$149 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $482 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,864 loss on $10,000 · 38.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The trials continue through 52 weeks. These results can test whether early symptom gains last and whether safety stays favorable.
Watch forAt 52 weeks, symptom gains remain strong and no new safety issue changes the favorable profile.
Also watch forAt 52 weeks, symptom gains fade or a new safety issue changes the favorable profile.
Why it matters: This study tests barzolvolimab in two more conditions. Enrollment progress can show whether the program keeps moving.
Supportive ifCelldex reports that enrollment continues in EMBARQ-ColdU and -SD. The study timeline has not changed.
Worry ifCelldex reports an enrollment delay or a change that pushes back the study timeline.